REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
To learn about the effects of the investigational drug NKTR-255 in combination with the
standard drug durvalumab on locally advanced NSCLC when given after CRT.